The gist
- A pool of mature memory B cells in some people churns out antibodies against their own type-I interferons, the proteins that fire the body’s first antiviral alarm. The alarm is jammed before any virus arrives.
- These antibodies are already in the blood before infection. That makes the flaw a pre-existing trait, not a consequence of getting sick, and a candidate you could screen for.
- Mapping hundreds of patient antibodies traced the whole attack to just three epitopes that blanket every type-I interferon, which is why the shutdown is so thorough.
The same virus, two very different outcomes
Two people breathe in the same virus. One shrugs it off in a few days. The other is fighting for breath in an ICU a week later. Why has been a nagging question since 2020, and a 2026 paper in Cell supplies a mechanical answer for a real slice of the severe cases. It is an unsettling one. The immune system has, in effect, disarmed itself in advance.
The work was led by Morgane Fournier with senior author Prof. Rabih Halwani, an immunologist at the University of Sharjah, pulling patient and lab samples from 12 countries across Europe, North America, the Middle East, and beyond. The self-inflicted target is type-I interferon. Picture it as a smoke detector wired into the antiviral response: an infected cell trips it, and the cells nearby lock down before the virus can multiply. In these patients, antibodies are already clamped onto the detector, muffling the signal.
These are not sloppy antibodies
The easy assumption would be a weak, incidental cross-reaction. That is not what the team found. The antibodies bind type-I interferon and neutralise it outright, and they have been honed to do exactly that.
The B cells making them carried heavy somatic hypermutation, the tell-tale of a long tour through a germinal centre, where B cells sharpen their aim over weeks. So the response is organised, matured, and self-directed, sitting quietly in the background and waiting for a virus to turn it into a liability. Because the interferon alarm is supposed to sound in the first hours of infection, silencing it precisely then hands the virus an unchecked head start early on, and that early window is often what decides whether a case stays mild or turns dangerous. Notably, the patients carrying this response looked, at the B-cell level, much like people whose interferon problems come from an inherited T-cell tolerance defect.
How three weak points explain a total shutdown
To see how the antibodies grip their target, the team pulled hundreds of monoclonal antibodies straight from patients and mapped the binding two ways, with X-ray crystallography and AlphaFold3 modelling.
What stood out was the economy. All those different antibodies funnel onto three major epitopes, and between them those three patches cover every important face of type-I interferon, IFN-alpha and IFN-omega alike. That is the reason the neutralisation is so complete. The antibodies are not picking off one interferon subtype; they smother the entire family with a handful of grips.
What a clinic could actually do with this
Prediction is the near-term payoff. If the autoantibodies are circulating before anyone falls ill, a blood assay could, in principle, flag the people most likely to crash, and not only from COVID-19. The authors extend the logic to severe influenza and to whatever coronavirus comes next: same silenced alarm, different pathogen. Older adults and people with known immune-tolerance defects are the obvious first groups to check.
Treatment sits further out. Stripping away or re-educating the B cells that make these antibodies is the logical target, and the paper names it as a direction rather than a therapy anyone can request today. So for now the value is a mechanism plus a plausible test. That is still enough to move “who ends up severely ill” out of the column marked bad luck and toward something you might read off a blood draw before the virus ever lands.
Sources:
- News-Medical, “Study identifies immune response causing severe COVID-19 susceptibility”
- Medical Xpress, “Study reveals why key antiviral defenses failed in some severe COVID-19 patients”
- Cell, “Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections” (Fournier et al., 2026)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.